Abstract
Flavonoids are new promising potential natural compounds for treating Alzheimers disease (AD). Actually most promising drugs for symptomatic treatment of AD are acetylcholinesterase inhibitors (AChEI). Flavonoids with AChE inhibitory activity and due to their well known antioxidant activity could be new multipotent drugs for AD treatment. This work focuses on natural and synthetic flavonoids inhibitors of the enzyme acetylcholinesterase (AChE). Over, all this review refers to 128 flavonoids, which are classified in chemical structure, and summarizes 64 references.
Keywords: Acetylcholinesterase inhibitors, Alzheimer's disease, flavonoids, antioxidant activity, structure-activity relationship, natural products, flavones, flavanones, flavonols, isoflavones, chalcones
Current Medicinal Chemistry
Title: Flavonoids as Acetylcholinesterase Inhibitors
Volume: 18 Issue: 34
Author(s): I. Uriarte-Pueyo and M. I. Calvo
Affiliation:
Keywords: Acetylcholinesterase inhibitors, Alzheimer's disease, flavonoids, antioxidant activity, structure-activity relationship, natural products, flavones, flavanones, flavonols, isoflavones, chalcones
Abstract: Flavonoids are new promising potential natural compounds for treating Alzheimers disease (AD). Actually most promising drugs for symptomatic treatment of AD are acetylcholinesterase inhibitors (AChEI). Flavonoids with AChE inhibitory activity and due to their well known antioxidant activity could be new multipotent drugs for AD treatment. This work focuses on natural and synthetic flavonoids inhibitors of the enzyme acetylcholinesterase (AChE). Over, all this review refers to 128 flavonoids, which are classified in chemical structure, and summarizes 64 references.
Export Options
About this article
Cite this article as:
Uriarte-Pueyo I. and I. Calvo M., Flavonoids as Acetylcholinesterase Inhibitors, Current Medicinal Chemistry 2011; 18 (34) . https://dx.doi.org/10.2174/092986711798184325
DOI https://dx.doi.org/10.2174/092986711798184325 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Individual Differences in the Neurobiology of Social Stress: Implications for Depression-Cardiovascular Disease Comorbidity
Current Neuropharmacology Preface [Hot Topic: Cannabinoid Receptors (Guest Editor: Maria L. Lopez-Rodriguez)]
Current Medicinal Chemistry - Central Nervous System Agents Platelet Activation in Atherogenesis Associated with Low-Grade Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Ring-Fused Thiadiazines as Core Structures for the Development of Potent AMPA Receptor Potentiators
Current Medicinal Chemistry Conference Report: 181<sup>st</sup> Annual Meeting of the American Association for the Advancement of Science (AAAS), San Jose Convention Center, San Jose, CA, USA February 12-16, 2015
CNS & Neurological Disorders - Drug Targets Potential Application of Induced Pluripotent Stem Cells in Cell Replacement Therapy for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Microwaves-Assisted Syntheses of Imidazolylbenzamides and their Antioxidant Activities
Letters in Drug Design & Discovery Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Substrate – Inositol Transporter Interactions: Molecular Docking Study
Letters in Drug Design & Discovery Choline Nutrition Programs Brain Development Via DNA and Histone Methylation
Central Nervous System Agents in Medicinal Chemistry Synthesis of piperidine-4-one Derivative Containing Dipeptide: An Acetyl cholinesterase and β-secretase Inhibitor
Anti-Infective Agents Severe Hyponatremia and Other Electrolyte Disturbances Associated with Indapamide
Current Drug Safety Conference Report: 6<sup>th</sup> Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Nov 14-16, 2013, The Westin San Diego Gaslamp Quarter Hotel, San Diego, CA, USA
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Relationship between Augmentation Index and Wall Thickening Fraction during Hypotension in an Animal Model of Myocardial Ischemia-Reperfusion and Heart Failure
Current Hypertension Reviews Medicinal Plants for the Treatment of Hair Loss and the Suggested Mechanisms
Current Pharmaceutical Design The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia
Current Alzheimer Research Traditional Chinese Medicine Network Pharmacology in Cardiovascular Precision Medicine
Current Pharmaceutical Design Nasal Neuro EPO Could be a Reliable Choice for Neuroprotective Stroke Treatment
Central Nervous System Agents in Medicinal Chemistry Inhibition of Amyloid-β Aggregation in Alzheimer's Disease
Current Pharmaceutical Design